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Imidazopyridazine compounds are potent, ATP-competitive inhibitors of calcium-dependent protein kinase 1 (CDPK1) and of
Plasmodium falciparum parasite growth in vitro. Here, we show that these compounds can be divided into two classes depend-
ing on the nature of the aromatic linker between the core and the R2 substituent group. Class 1 compounds have a pyrimidine
linker and inhibit parasite growth at late schizogony, whereas class 2 compounds have a nonpyrimidine linker and inhibit
growth in the trophozoite stage, indicating different modes of action for the two classes. The compounds also inhibited cyclic
GMP (cGMP)-dependent protein kinase (PKG), and their potency against this enzyme was greatly reduced by substitution of the
enzyme’s gatekeeper residue at the ATP binding site. The effectiveness of the class 1 compounds against a parasite line express-
ing the modified PKG was also substantially reduced, suggesting that these compounds kill the parasite primarily through inhi-
bition of PKG rather than CDPK1. HSP90 was identified as a binding partner of class 2 compounds, and a representative com-
pound bound to the ATP binding site in the N-terminal domain of HSP90. Reducing the size of the gatekeeper residue of CDPK1
enabled inhibition of the enzyme by bumped kinase inhibitors; however, a parasite line expressing the modified enzyme showed
no change in sensitivity to these compounds. Taken together, these findings suggest that CDPK1 may not be a suitable target for
further inhibitor development and that the primary mechanism through which the imidazopyridazines kill parasites is by inhi-
bition of PKG or HSP90.
There is a great need to identify novel targets for antimalarialtherapeutic intervention (1) since the eventual selection of re-
sistance to drug treatments has repeatedly been a problem in the
treatment of malaria (2). This is exemplified by the emergence of
Plasmodium falciparum strains displaying delayed clearance by the
current treatment of choice, artemisinin and its derivatives, and it
is considered inevitable that artemisinin resistance will eventually
develop and spread (3–5). Recentlymutations in the kelch propel-
ler domain protein, K13-propeller, have been shown to be associ-
ated with artemisinin resistance in vitro and in vivo (6). New
drugs, acting on novel targets, are clearly needed in the ongoing
fight against malaria. It is for these reasons that Plasmodium pro-
tein kinases are now being considered potential drug targets (7, 8).
Calcium-dependent protein kinase 1 (CDPK1) is an abun-
dant protein expressed in many stages of the Plasmodium life
cycle. It is indispensable for the development of sexual stages of
Plasmodium berghei, playing a role in activating translation of
repressed mRNAs (9). In the asexual blood stages, the protein is
found at the periphery of merozoites and is associated with the
parasite plasmamembrane by virtue ofmyristoylation and palmi-
toylation of its N terminus (10, 11). Its function in blood stages is
elusive, with suggestions that it may play a role in regulating par-
asite motility. The location of the protein on the inner face of the
plasma membrane makes it ideally placed to phosphorylate com-
ponents of the parasite’s motor complex that is anchored to both
the parasite plasma membrane (PPM) and the inner membrane
complex (IMC).While it has been demonstrated that CDPK1 can
phosphorylate the myosin light chain MTIP (myosin A tail do-
main-interacting protein) and the glideosome-associated protein
GAP45 in vitro (10) and that these proteins are modified accord-
ingly in the parasite (12–14), there is no direct evidence that
CDPK1 is responsible in vivo. An early study in P. falciparum sug-
gested that while the cdpk1 gene was amenable to genetic manip-
ulation, it was not possible to knock the gene out (15). This sug-
gested an essential role for the protein in blood stages. Initial
Received 20 July 2015 Returned for modification 4 August 2015
Accepted 1 December 2015
Accepted manuscript posted online 28 December 2015
Citation Green JL, Moon RW, Whalley D, Bowyer PW, Wallace C, Rochani A,
Nageshan RK, Howell SA, Grainger M, Jones HM, Ansell KH, Chapman TM, Taylor
DL, Osborne SA, Baker DA, Tatu U, Holder AA. 2016. Imidazopyridazine inhibitors
of Plasmodium falciparum calcium-dependent protein kinase 1 also target cyclic
GMP-dependent protein kinase and heat shock protein 90 to kill the parasite at
different stages of intracellular development. Antimicrob Agents Chemother
60:1464–1475. doi:10.1128/AAC.01748-15.
Address correspondence to Judith L. Green, judith.green@crick.ac.uk, or Anthony
A. Holder, tony.holder@crick.ac.uk.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/AAC.01748-15.
Copyright © 2016 Green et al. This is an open-access article distributed under the
terms of the Creative Commons Attribution 3.0 Unported license.
crossmark
1464 aac.asm.org March 2016 Volume 60 Number 3Antimicrobial Agents and Chemotherapy
attempts to delete cdpk1 in P. berghei also proved unsuccessful
(16); however, in a more recent study the gene was successfully
deleted (17).
Apicomplexan CDPKs have been the subject of several drug
development programs; these have been summarized in a recent
review article (18). There have been a number of studies describ-
ing the development of small-molecule inhibitors of CDPK1. For
example, the 2,6,9-trisubstituted purine purfalcamine, which
blocks P. falciparum growth, has been shown by affinity purifica-
tion to bind to CDPK1 (15). Parasites treated with purfalcamine
do not progress through asexual blood stage development, arrest-
ing when they are very mature schizonts. This inhibition of mero-
zoite egress suggested a possible role for CDPK1 in this process
(15). In a second study, two series of small-molecule inhibitors
that were competitive for ATP binding to CDPK1 were described
(19). We have previously described a series of imidazopyridazine
compounds that are potent inhibitors of CDPK1 in vitro, with
50% inhibitory concentrations (IC50s) in the subnanomolar range
(20–23). These inhibitors are ATP competitive; their binding to
the recombinant kinase was reduced by a large amino acid at the
gatekeeper position and at high concentrations of ATP. Although
the most potent of the compounds exhibited a 50% effective con-
centration (EC50) of 12 nM for killing P. falciparum in culture, the
compounds performed disappointingly in a rodent model of ma-
laria infection. In addition, one puzzling feature of these inhib-
itors was the poor correlation between their ability to inhibit
the enzyme and their ability to block parasite growth, which
was suggestive of off-target activity contributing to their inhib-
itory effects (23).
Here, we examine the mechanism of action of some of the
inhibitors described previously and show that they fall into two
classes, causing parasite death at two distinct points of the asexual
blood stage cycle. We have identified the likely additional target
proteins of each class of compound and have been able to identify
features of the compounds that confer this selectivity. Further-
more, using a chemical genetics approach,we show that inhibition
of CDPK1 does not appear to affect blood stage parasite growth or
survival, leading us to conclude that CDPK1may not be a suitable
target for pharmaceutical intervention for the treatment of blood
stage malaria infection.
MATERIALS AND METHODS
Parasite lines and culture methods. All P. falciparum lines were main-
tained in human erythrocytes provided by the National Blood Transfu-
sion Service. 3D7 is a cloned line obtained from the University of Edin-
burgh. The 3D7 cyclic GMP (cGMP)-dependent protein kinase (PKG)
with a T618Q substitution has been described previously (24). Parasites
were grown at 2% hematocrit in RPMI 1640 medium supplemented with
1% Albumax according to published methods (25). Synchronization was
achieved by centrifugation through a Percoll gradient (26).
Drug treatment and SYBR green assay. Aliquots of 100 l of P. fal-
ciparum cultures 24 h after erythrocyte invasion were transferred into
96-well culture dishes. Cells were incubated with inhibitors for 48 or 96 h
(starting parasitemias were 0.3% and 0.03%, respectively). All drug treat-
ments were carried out in duplicate at a final dimethyl sulfoxide (DMSO)
concentration of 0.05%. After incubation, a modification of a previously
described SYBR green assay was performed (27). Cells were lysed by the
addition of 25 l of buffer (20 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH
8.0, 1.6% Triton X-100, 0.16% saponin, 10 SYBR green I [Life Technol-
ogies]). After incubation in the dark for 2 h, fluorescence of the samples
was determined using a FLUOStar Omega plate reader (BMG Labtech)
with excitation and emission filters of 485 nm and 520 nm, respectively.
EC50s were calculated from a four-parameter logistical fit of the data
using Prism software (GraphPad Software, Inc.). The compounds
1-(1, 1-dimethylethyl)-3-(1-naphthalenyl)-1H-pyrazolo[3,4-d]py-
rimidin-4-amine (NA-PP1) and 1-(1, 1-dimethylethyl)-3-(1-naph-
thalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (NM-PP1)
were obtained from Merck.
Generation and screening of parasites expressing gatekeeper mu-
tant CDPK1. Parasites expressing CDPK1 T145G and CDPK1 T145T
were generated as described previously (28). Briefly, a region of homology
to facilitate integration of the plasmid via single-crossover homologous
recombination was amplified from P. falciparum 3D7 genomic DNA at
194 bp upstream of the ATG to bp 435 of the open reading frame using
primers 1 and 2 for thewild-type (WT) version and primers 1 and 3 for the
glycine version. Each of these fragments was cloned via XmaI and EcoRI
sites into a Geneart vector containing a recodonized gene fragment from
bp 436 to 1572 of the P. falciparum cdpk1 (Pfcdpk1) open reading frame.
Together, the native and recodonized cdpk1 sequences were cloned
between XmaI and AvrII sites of the pHH4-HA plasmid (29), which
adds a triple hemagglutinin (HA) tag at the 3= end, followed by a stop
codon and the PbDT-3= UTR (the 3= untranslated region of the P.
berghei dihydrofolate reductase [DHFR]-thymidylate synthase) and hu-
manDHFR (hDHFR) drug selection cassette. Primers were the following:
primer 1, ACACCCCGGGGTATACAACGTATAAGACAAATTACTTT
TCTTTC; primer 2, ATATGAATTCGGTTACTAAATAAAAATATTTCT
TATCTTCAAAAACATCAAAC; primer 3, ATATGAATTCGCCTACTA
AATAAAAATATTTCTTATCTTCAAAAACATCAAAC.
P. falciparum 3D7 parasites were transfected with pHH4-CDPK1-HA
plasmids (T145T or T145G) using standard methods (30, 31). They were
maintained under drug pressure (25 nM WR99210) until resistant para-
sites emerged, cycled on/off drug, and cloned by limiting dilution.
Cloneswere screened by PCRusing primers 4 and 5 to detect the intact
locus and primers 4 and 6 to confirm integration, as well as by Western
blotting and immunofluorescence using anti-CDPK1 and anti-HA anti-
bodies. The following are the primer sequences: primer 4, GATGGTGGC
ACTTGCCTTTTTGAGG; primer 5, CTGGTTTAATATCTCGATGTAC
AATATTATGTTTATG; primer 6, CCCAATCTGTCCCTTAGCTTGTT
GTC.
Western blotting and immunofluorescence. Late-schizont-stage
parasites were lysed in 1% NP-40, 150 mM NaCl, and 10 mM Tris-HCl,
pH 8.0, containing 1 Complete protease inhibitors (Roche). After cen-
trifugation for 20 min at 15,000  g, 10 g of soluble protein was sepa-
rated on a 10% Bis-Tris NuPAGE gel (Life Technologies). Transfer to a
nitrocellulosemembranewas performedusing an iBlot system (Life Tech-
nologies). Antibodies against HA (rat monoclonal antibody 3F10; Roche)
and CDPK1 (10) were used to detect modified or total CDPK1, respec-
tively, using standard methods.
Recombinant protein production. PfCDPK1 and PfCDPK1 T145G
proteins were produced using methods described elsewhere (23). The
PfHSP90 N-terminal domain (NTD) comprises the first 223 amino acids
of PfHSP90. This region was amplified from the full-length PfHSP90-
pRSET-A construct (32) using the following primers: primer 7, GGCGA
CGGATCCATGTCAACGGAAACATTCGC; primer 8, GACCCCCTCG
AGCTATTCTTCTTCAGATGCGG.
The PCR product was cloned into pRSET-A (Life Technologies) be-
tween the BamHI and XhoI sites. Positive clones were confirmed by re-
striction digestion and sequencing. The clone was transformed into Esch-
erichia coli Rosetta(pLysS) cells, and protein was expressed by induction
with 0.1mM isopropyl-D-1-thiogalactopyranoside (IPTG) at 37°C for 2
h. PfHSP90 proteins were purified using Ni-nitrilotriacetic acid (NTA)
affinity chromatography (Qiagen) as described in themanufacturer’s pro-
tocol.
ParM ADP biosensor assay. IC50s were determined in kinetic mode
using a rhodamine-labeled ParM (Rh-ParM) ADP sensor (33). For these
experiments 5l of PfCDPK1 (WT or T145G) was diluted in assay buffer
(50mMTris-HCl, pH 8.0, 200MCaCl2, 1mMdithiothreitol [DTT], 25
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mM KCl, 100 M EGTA, and 0.01% [vol/vol] Triton X-100) to a final
concentration of 100 nM and mixed with 10 l of Rh-ParM at a final
concentration of 100 nM in black 384-well plates (Corning). Compounds
were diluted in half-log series in DMSO, and 2-l volumes of diluted
compound, or DMSO alone, were added to the enzyme and incubated for
30 min at room temperature. A further control reaction had DMSO but
no enzyme. The reactionwas initiatedwith 5l of 20mMMgCl2 andATP
at the appropriate previously determinedKm values (23) of 30Mand 90
M ATP for WT CDPK1 and CDPK1 T145G, respectively. IC50s were
calculated from a four-parameter logistical fit of the data using Prism
software (GraphPad Software Inc.).
Expression and purification of recombinant PKG. Full-length Pf-
PKG and PfPKG T618Q were prepared as described previously (24,
34). Briefly, plasmids (pTrcHisC) encoding full-length PfPKG and
PfPKG T618Q with N-terminal His tags were transformed into E. coli
Rosetta2(DE3). Single colonies were grown in LB rich broth (supple-
mented with 50 g/ml carbenicillin and 34 g/ml chloramphenicol) at
37°C. Protein expression was induced with 1 mM IPTG once an optical
density of 0.6 to 0.7 had been reached. Subsequent overnight growth was
at 16°C. PKGs were purified via the histidine tag on HiTrap Talon col-
umns (GE Healthcare) according to the manufacturer’s instructions and
then concentrated on 10-kDa-molecular-mass-cutoff concentrators
(Amicon). Purified proteins were stored in 50% glycerol at 80°C in
single-use aliquots. Final buffer composition of the purified product was
50mMTris-HCl, pH 7.5, 0.1mMEGTA, 150mMNaCl, 0.1%-mercap-
toethanol, 50% glycerol, 0.03% Brij-35, 1 mM benzamidine, and 0.2 mM
phenylmethylsulfonyl fluoride (PMSF).
Assay of cGMP-dependent protein kinase activity. IC50s were deter-
mined for test compounds using a microfluidic fluorescent shift assay
(unpublished data). Briefly, compounds were prepared over a 10-well
half-log dilution series in DMSO in duplicate in 50-l volumes using
96-well polypropylene U-bottomed plates (Thermo Scientific, United
Kingdom). The reaction mix for each well consisted of 20 l of enzyme/
peptide mix (1.25 nM PfPKG or PfPKG T618Q, 1.5 M 6-carboxyfluo-
rescein [FAM]-labeled PKAtide [FAM-GRTGRRNSI-NH2; Cambridge
Bioscience, United Kingdom] in PfPKG assay buffer [25mMHEPES (pH
7.4), 20 mM -glycerophosphate, 2 mMDTT, 10 M cGMP, 0.01% (wt/
vol) bovine serum albumin (BSA), 0.01% (vol/vol) Triton X-100]) plus 5
l of compound. Samples were preincubated at room temperature for 30
min, and reactions were initiated by addition of 25l of ATPmix (10mM
MgCl2 andATP, at theKm of the enzyme under test [20MPfPKG and 90
M PfPKG T618Q], in water). Reactions were terminated at approxi-
mately 10% substrate conversion by addition of 50l of stop solution (25
mM EDTA in water). Samples were analyzed by electrophoretic separa-
tion of substrate and product peak and fluorescence detection using a
Caliper LabChip EZ Reader (PerkinElmer, Waltham MA) with a 0.2-s
buffer sip time, downstream voltage of 500 V, upstream voltage of 1,950
V, and pressure of 0.5 to 1.5 lb/in2. IC50s for the compounds were deter-
mined using a four-parameter logistical fit of the data (GraphPad Prism).
Synthesis of biotinylated compound D. The chemical synthesis of
compound D with biotin attached to the R1 or R2 group is described in
Information S1 in the supplemental material.
Affinity purification of targets of compound D. A total of 200 l of
high-capacity streptavidin agarose (Thermo Scientific) was resuspended
in 1 ml of 250 g/ml biotinylated compound D solution or a DMSO
control. After incubation with mixing for 1 h at room temperature, un-
bound compound was removed by extensive washing with phosphate-
buffered saline (PBS). The resin was incubated with trophozoite lysate
containing 2 mg of protein in a total volume of 1.5 ml overnight at 4°C.
The lysate was prepared by resuspending trophozoites in 20 mM Tris-
HCl, pH 8.0, 10 mM MgCl2, 250 mM NaCl, 0.5 mM tris(2-carboxy-
ethyl)phosphine (TCEP), 1 protein phosphatase inhibitor (Sigma-
Aldrich), 1 complete protease inhibitors (Roche), and 0.1% Triton
X-100 (Sigma-Aldrich). Insoluble proteins were removed by centrifu-
gation at 15,000  g for 20 min, and protein was quantitated using a
detergent-compatible (DC) protein assay (Bio-Rad). The resin was ex-
tensively washed in lysis buffer to remove unbound proteins, and proteins
were eluted by resuspending the resin in 100 l of 2 reducing lithium
dodecyl sulfate (LDS) sample buffer (Life Technologies) and heated at
95°C for 5 min.
Proteins were run 4 mm into a 10% NuPAGE Bis-Tris gel (Life Tech-
nologies) and then excised using a clean scalpel blade. Proteins were re-
duced and alkylated prior to overnight trypsin digestion. The resulting
digests were analyzed by liquid chromatography-tandemmass spectrom-
etry (LC-MS/MS) using an Ultimate 3000 nanoRSLC high-performance
liquid chromatograph (HPLC), equipped with a 50-cm by 75-m Ac-
claim Pepmap C18 column, coupled to a linear trap quadrupole (LTQ)
Orbitrap Velos Pro equipped with a Nanoflex electrospray source (all
Thermo Scientific). A gradient of 6 to 32% acetonitrile–0.1% formic acid
over 48 min was used at a flow rate of 0.3 l/min. The Orbitrap was
operated in data-dependent acquisition mode with a survey scan at a
resolution of 60,000, and up to the 10 most intense ions were selected for
MS/MS. Raw files were processed using Proteome Discoverer (PD), ver-
sion 1.3 (Thermo Scientific) with Mascot, version 2.4 (Matrix Science,
United Kingdom), as the search engine against the appropriate protein
database. A decoy database of reversed sequences was used to filter the
results at a false detection rate of 1%.
Kd (dissociation constant) determination for 17-AAG and com-
pound D binding to PfHSP90.Tryptophanfluorescence analysiswas per-
formed using a PerkinElmer LS55 luminescence spectrometer. In order to
determine the binding affinity of purified recombinant proteins, 25g/ml
PfHSP90 or PfHSP90 N-terminal domain (PfHSP90-NTD) was incu-
batedwith concentrations of 17-N-allylamino-17-demethoxygeldanamy-
cin (17-AAG) or compound D ranging from 0 to 60 M. The binding
buffer used for the reaction contained 50mMTris-HCl, pH7.4, and 1mM
EDTA. Samples were excited at 280 nm, and tryptophan fluorescence
measurements were carried out by scanning the emission spectrum in the
wavelength range 300 to 400 nm. A maximum wavelength (max) of 346
nm was selected for all the calculations. The slit widths of excitation and
emission were set at 2.5 and 5 nm, respectively. The difference in fluores-
cence intensity between protein alone and protein with various concen-
trations of 17-AAGor compoundDwas calculated and plotted against the
different concentrations of the respective ligand used. The resultant hy-
perbolic curve was analyzed with GraphPad Prism software, using non-
linear regression analysis with single-site-specific binding as described
previously (32).
Docking compound D to PfHSP90. Docking calculations were per-
formed using the web-based graphical user interface (GUI) of Docking-
Server by Virtua Drug (Budapest, Hungary) (35). The PfHSP90 N-termi-
nal domain structure was downloaded from the ProteinData Bank (PDB)
(PDB accession number 3K60) (36). Chain A of the dimeric PfHSP90 was
used to performdocking calculations. Essential hydrogen atoms, Kollman
united atom type charges, and solvation parameters were added with the
aid of AutoDock tools (37). An affinity map of 20-by-20-by-20-Å grid
points, and 0.375-Å spacing was developed using the AutoGrid program
(37). Test and control ligand structures were subjected to geometry opti-
mization, and charge calculations were performed using the Merck mo-
lecular force field 94 (MMFF94) andGasteigermethods, respectively (38).
Here, Gasteiger partial charges were added to the ligand atoms. Nonpolar
hydrogen atoms were merged, and rotatable bonds were defined. Auto
Dock parameter set and distance-dependent dielectric functions were
used in the calculation of the van der Waals and the electrostatic terms,
respectively.
The prepared molecular structures were subjected to docking simula-
tion using the Lamarckian genetic algorithm (LGA) and the Solis and
Wets local search method (39) which is used by the DockingServer GUI.
All rotatable torsions were released during docking. During the search, a
translational step of 0.2 Å and torsional steps of 5.0 Å were applied. Dock-
ing calculations are the result of 10 autonomous runs. Each run was ter-
minated after a maximum of 250,000 energy evaluations. The population
Green et al.
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size was set to 150. Here, we used free energy of binding (kcal/mol), num-
ber of hydrogen bond interactions, inhibition constant (Ki), and fre-
quency of probable binding sites for ranking our docking results. Fre-
quency shows the percentage of the local searches with similar geometry
having a root mean square tolerance (rmstol) of 2 Å. Docked structures
with the lowest free energy of binding andKi values and structures having
two or more hydrogen bond interactions between ligand and protein and
a frequency of 10% or more were used for prediction of the probable
binding configuration for compound D. The analyzed PDB format of the
docking file was downloaded and analyzed using Discovery Studio Visu-
alizer, version 4.0.
RESULTS
Imidazopyridazines target two distinct stages of asexual para-
site development. Previously, we developed a series of potent
CDPK1 inhibitors based on an invariant imidazopyridazine
central core, an aromatic linker group (A in Fig. 1A), and vari-
able R1 and R2 groups (Fig. 1A). Some of these compounds
inhibit recombinant CDPK1 with low-nanomolar IC50s and
are extremely effective at killing parasites in culture, with the
most potent compound having an EC50 of 12 nM (20–23). To
determine their modes of action against the parasite, we added
the compounds to synchronized parasite populations and identified
atwhich stage they inhibitedgrowth.ExaminationofGiemsa-stained
smears of parasites treated at the ring stage with imidazopyridazines
at 10 times their parasiticidal EC50s revealed that the compounds had
two distinctmechanisms of action during intracellular development.
Some (designated class 1 compounds) killed parasites at the mature
schizont stage late in the cycle, while others (class 2 compounds)
killed parasites at the early trophozoite stage (Fig. 1B). In the former
case, while parasites developed into schizonts in the presence of the
compounds, they did not rupture the erythrocyte to releasemerozo-
ites.
FIG 1 Imidazopyridazine compounds have two modes of action. (A) Imidazopyridazine compounds in this study are characterized by an invariant core, an
aromatic linker group (A), and variable R1 and R2 groups. (B) P. falciparum 3D7 parasites approximately 21 h after merozoite invasion of erythrocytes were
incubated for 48 h with a concentration equal to 10 times the EC50 of each compound (determined by fluorescence-activated cell sorting [23]). In mock-treated
cultures (0.05%DMSO), newly invaded erythrocytes with ring stage parasites are seen. In the presence of compoundC (CpdC; 0.3M), parasites developed until
very late schizogony and then arrested prior to merozoite egress, whereas with compound D (CpdD; 4 M), parasites failed to develop beyond late rings/early
trophozoites. (C) EC50 determination using a SYBR green I assay. P. falciparum cultures were incubated for either 48 h or 96 hwith serial dilutions of inhibitors. For
compound A, the EC50 with 48 h of incubation was not able to be determined with any accuracy, whereas with 96 h of incubation the EC50 was 0.023 M (standard
deviation, 0.007). The EC50 for compound E was 0.298 M (standard deviation, 0.066) or 0.142 M (standard deviation, 0.024) with 48 h or 96 h of incubation,
respectively. The graphs shown are representative examples of triplicate experiments. Error bars show the standard errors of the means for duplicate samples.
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As a higher-throughput alternative to microscopic examina-
tion, we used a fluorescence-based assay tomeasure parasite DNA
content. Briefly, a trophozoite population collected 21 h after
merozoite invasion of erythrocyteswas incubatedwith compound
for either 48 or 96 h, representing one or two rounds of parasite
replication, respectively. Parasites were then lysed in the presence
of SYBR green I, a fluorescent dye that binds preferentially to
double-stranded DNA. After 48 h of incubation, parasites treated
with compounds that kill following DNA replication are indistin-
guishable from untreated cells because an arrested schizont will
give the same net fluorescence as parasites from a ruptured schi-
zont that have gone on to invade red blood cells. Extending the
culture period after drug addition to 96 h enables a true EC50 to be
measured for all compounds because another round of parasite rep-
licationwillhaveoccurred inviableparasites.TheEC50smeasured for
compounds that act prior to DNA synthesis will be identical regard-
less of the incubation time, whereas compounds that act after DNA
synthesiswill appear tobemuch less potent in the shorter-incubation
assay. Use of these two measures enabled compounds to be
classified based on the stage at which they killed parasites. Class
1 compounds act after DNA synthesis in late schizogony and
prior to merozoite release, whereas class 2 compounds act at
the trophozoite stage prior to DNA synthesis. Graphs for ex-
emplar compounds of each class are shown in Fig. 1C.
We analyzed 41 compounds in this manner in order to define
the molecular features that determine their modes of action (see
Table S1 in the supplemental material). For each compound, the
EC50s were measured at 48 h (EC5048) and 96 h (EC5096), and the
ratio of the EC50s was calculated; an EC5048/EC5096 ratio greater
than 5 was a strong indication that a compound acted after DNA
synthesis.When the structure of each compound was examined, a
determinant of the stage at which the compound acted was the
presence or absence of a pyrimidine at the aromatic linker posi-
tion (labeled A in Fig. 1A). Of the 16 compounds with a pyrimi-
dine linker, 13 had anEC5048/EC5096 ratio greater than 5, suggest-
ing that their action was after DNA synthesis (class 1). Of the 25
compounds with nonpyrimidine linkers, 24 had an EC5048/
EC5096 ratio less than 5, suggesting that their action was prior to
DNA synthesis (class 2). Full details are provided in Table S1. This
classification was again confirmed bymicroscopic examination of
Giemsa-stained blood smears of parasites treated with a subset of
10 compounds (Table 1; see also Table S1 in the supplemental
material). Compound 28was the only class 1 compound shown in
Table 1 with an EC5048/EC5096 ratio less than 5 and was con-
firmed by microscopy to arrest parasites in late schizogony, indi-
cating that while an EC5048/EC5096 ratio greater than 5 is sugges-
tive of action after DNA replication, borderline cases need to be
confirmed by microscopy. The majority of class 1 compounds (9
of 16) have EC5048/EC5096 ratios greater than 500.
Late-acting compounds kill parasites by inhibiting cGMP-
dependent kinase (PKG). We first wished to identify the target of
the class 1 inhibitors in the parasite since, although they act very
late in schizogony, they may be acting through a target other than
CDPK1. For example, the phenotype of parasites treatedwith pur-
falcamine, a previously reported CDPK1 inhibitor (15), is very
reminiscent of the phenotype of those treated with cGMP-depen-
dent protein kinase (PKG) inhibitors such as “compound 1,” in
whichmerozoites develop within the schizont but are not released
because of a defect in egress (40). While it is not impossible that
the phenotype of CDPK1 inhibition is indistinguishable from that
of PKG inhibition, we wished to definitively identify the primary
target(s) of our compounds. CDPK1 and PKG are closely related
kinases with regard to ATP binding sites; for example, they share
some sequence homology, including a small threonine residue at
the gatekeeper position (residue 145 in CDPK1 and residue 618 in
PKG). The imidazopyridazine compounds in this study have been
shown to interact at the ATP binding site of recombinant CDPK1
in vitro, and this binding was blocked by replacing the gatekeeper
residue with the larger glutamine, which blocks access to the en-
zyme’s binding pocket, rendering it relatively insensitive to spe-
cific inhibitors (23). In a similar chemical genetics approach, the
gatekeeper residue of PKG had also been replaced by glutamine
(24).
We tested the ability of 30 compounds to inhibit PKG and their
sensitivity to a large residue at the gatekeeper position. All of the
compounds inhibited recombinant PKG activity, with the most
TABLE 1 Compounds divided into two classes based on the aromatic linker
Class and compounda Aromatic linker
EC50
b (M ) after treatment for:
EC5048/EC5096 ratio Stage of action
c48 h 96 h
Class 1
28 Pyrimidine 0.168 (0.011) 0.038 (0.012) 4.4 Late schizont
31 Pyrimidine 1.663 (0.650) 0.238 (0.047) 7.0 Late schizont
35 Pyrimidine 1,000 0.809 (0.451) 1,000 Late schizont
36 (Cpd A) Pyrimidine 1,000 0.023 (0.007) 1,000 Late schizont
38 Pyrimidine 1,000 0.050 (0.018) 1,000 Late schizont
39 (Cpd B) Pyrimidine 1,000 0.020 (0.008) 1,000 Late schizont
41 (Cpd C) Pyrimidine 1,000 0.037 (0.005) 1,000 Late schizont
Class 2
7 (Cpd D) Pyridine 0.355 (0.083) 0.311 (0.103) 1.1 Trophozoite
20 (Cpd E) Fluoropyridine 0.298 (0.066) 0.142 (0.024) 2.1 Trophozoite
22 Pyridine 0.546 (0.080) 0.300 (0.141) 1.8 Trophozoite
a Class 1, pyrimidine linker; class 2, nonpyrimidine linker. Cpd, compound
b EC50s of compounds were determined using a SYBR green I assay following treatment of parasite cultures with serial dilutions of the compounds for 48 h or 96 h. Data presented
show the mean EC50 values from three independent experiments, with the standard deviations shown in parentheses.
c The stage of action was determined by microscopic examination of Giemsa-stained parasite smears after treatment of ring stage parasites with 10 times the 96-h EC50 of
compound for 48 h.
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potent compound having an IC50 of 1.55 nM (see Table S2 in the
supplemental material). We have shown previously that the cor-
relation between the IC50 for CDPK1 and the P. falciparum EC50
for these compounds was poor (23). When compounds were
grouped according to class 1 and 2, there was an excellent corre-
lation between PKG IC50 and parasite-killing EC50 when the aro-
matic linkerwas a pyrimidine (class 1) (Fig. 2A, panel i).When the
linker group was not a pyrimidine (class 2), the correlation was
poor (Fig. 2A, panel ii). All of the compounds tested against PKG
relied on the presence of a small gatekeeper residue for their ac-
tivity. Replacing threonine 618 with glutamine resulted in an in-
crease in the IC50 by a factor of between 20 and over 16,000 (Table
2; see also Table S2 in the supplemental material).
To establish whether PKG was the primary target of the inhib-
itors in the parasite, we used a parasite line expressing a variant
PKGT618Q enzyme (24) andmeasured the EC50 of six class 1 and
five class 2 compounds against 3D7 wild-type (WT) and PKG
T618Q parasites, using the SYBR green I assay described previ-
ously, with a 96-h incubation time. We also included compound
1, a trisubstituted pyrrole previously shown to be an apicompl-
exan PKG inhibitor that is also sensitive to the size of the gate-
keeper residue (24). All but one of the class 1 compounds had
decreased parasiticidal activity against the PKG T618Q variant
parasite, with compound B (a class 1 compound) showing the
greatest effect, a 29-fold decrease in potency (Table 2 and Fig. 2B).
The exception is compound 44, a class 1 compoundwith an isobu-
tyl aliphatic group at position R2, whereas the other compounds
have fluorophenyl R2 groups. It is possible that the smaller ali-
phatic R2 group enables this compound to bind to the modified
enzyme, despite the large gatekeeper residue. Examination of Gi-
emsa-stained smears of 3D7 parasites treated at the ring stage with
compound 44 at its EC90 (0.65M) showed that the parasiteswere
arrested at the schizont stage, suggesting that it behaves like other
class 1 compounds in terms of its mode of parasite killing. Com-
pound 1 showed a 7-fold decrease in potency against the PKG
T618Q parasite, in line with previously published data (24, 40). In
contrast, none of the class 2 compounds (nonpyrimidine linker
group) showed a significant increase in the EC50 against the PKG
T618Q parasite, (Table 2; see also Table S2 in the supplemental
material). To determine the statistical significance of the differ-
ence between the two classes of compounds, aMann-Whitney test
was performed. The median ratio of the EC50 for 3D7 PKG
T618Q/EC50 for 3D7 of class 1 compounds was 16.8, and for class
2 compounds the median EC50 ratio was 1.4. The P value was
calculated to be 0.0043, indicating that the difference between
these two classes of compounds is significant (Fig. 2C). Taken
together, these data strongly suggest that the class 1 compounds
FIG 2 Parasite killing activity of class 1 compounds can be attributed to inhibition of cGMP-dependent protein kinase. (A, panel i) Correlation between P.
falciparum EC50 and PKG IC50 for 13 class 1 compounds. The calculated coefficient of determination (r
2) value of 0.71 from a linear least-squares regression
indicates a good correlation between the two data sets. A P value of 0.0002 indicates a significant relationship between the two measurements. The correlation
between P. falciparum EC50 and PKG IC50 for 16 class 2 compounds is also shown (panel ii). An r
2 of 0.17 indicates little correlation between the 3D7 EC50 and
the PKG IC50 for class 2 compounds. In addition, a P value of 0.114 indicates that there is no significant relationship between the two measures. (B) Parasites
expressing a large gatekeeper variant PKG (3D7 PKG T618Q) are insensitive to compound C compared to the sensitivity ofWT parasites (3D7 PKGWT). SYBR
green assays were used to measure the parasitemia of cultures treated with serial dilutions of compound C for 96 h. The experiment was performed twice; data
from a single experiment are shown. The EC50s are 0.923M(standard deviation, 0.226) for 3D7 PKGT618Q and 0.042M(standard deviation, 0.018) for 3D7
PKGWTparasites. Error bars represent the standard errors of themeans of duplicate samples. (C)Mann-Whitney test to compare the ratio of EC50s for 3D7PKG
T618Q/3D7WT PKG treated with class 1 and class 2 compounds. Horizontal bars show the median values for each class of compounds (16.8 for class 1 and 1.4
for class 2). The calculated P value is 0.0043.
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exert their parasiticidal effect primarily through inhibition of PKG
activity, whereas the class 2 compounds do not.
Early-acting compounds may kill parasites by inhibiting
HSP90. The early stage of the asexual cycle targeted by class 2
compounds precludes the target from being CDPK1 as it is not
expressed in such early parasites (41–43). To identify their target,
we selected an exemplar class 2 compound, compound D, resyn-
thesized it with biotin attached to the R1 group (Fig. 3A), and
made an affinity resin using streptavidin agarose. We purified in-
teracting proteins from a lysate prepared from infected erythro-
cytes approximately 24 h after invasion by merozoites and identi-
fied interacting proteins by LC-MS/MS. For proteins to be defined
as hits they had to be present in replicate LC-MS/MS analyses with
compoundD resin and absent fromduplicate control resin assays,
one with unloaded streptavidin and another where the biotin was
attached to the R2 group.
Most of the proteins detected were very weak hits, with fewer
than five unique peptides identified. The only exception was
HSP90 (PF3D7_0708400), which had 24 unique peptide hits (see
Table S3 in the supplemental material). HSP90 is a protein chap-
eronewith anATP binding site in its N-terminal domain. Using in
silico methods, we judged that the free energy of binding of com-
pound D to the ATP binding pocket of PfHSP90 was favorable;
Fig. 3B shows the residues of PfHSP90 predicted to interact with
compound D, and Fig. 3C shows the most likely binding orienta-
tion of the compound. From the docking simulation it can be
predicted that compound D will form both polar and hydropho-
bic interactionswith the amino acid residues in the binding pocket
of PfHSP90. Our analysis suggests that the nitrogen atom of the
piperidine groupmay attain a quaternary state to form a hydrogen
bond interaction with the carboxyl group of Asp40. In the given
orientation, the amino linker between the imidazopyridazine and
piperidine groups might also form a hydrogen bond interaction
with Asn37. Further, the pyridine (aromatic linker) in compound
D could form a mixed pi-alkyl hydrophobic interaction with
Leu93.We found that the amino alkyl branched chain attached to
the aromatic linker may also interact with Leu34, Ala38, and
Ile173 to promote the formation of a stable protein-ligand com-
plex. In addition, Phe124may interactwith the imidazopyridazine
nucleus of compound D by both pi and alkyl hydrophobic inter-
actions. TheGibbs binding free energy for the selected orientation
of compoundD in the binding pocket of PfHSP90was found to be
7.42 kcal/mol, with a root mean square tolerance (rmstol) of 2
Å. It is well established that the Kd value of a compound depends
on the Gibbs binding free energy (44). The Ki value for the com-
poundwas predicted to be 3.64M.The interaction of compound
D with recombinant PfHSP90 and the N-terminal domain of
HSP90 (PfHSP90-NTD) in vitro was confirmed by measuring
changes in intrinsic tryptophan fluorescence values upon binding
(32). The Kd values obtained for compound D binding to full-
length PfHSP90 and PfHSP90-NTD were 6.17 and 10.73 M, re-
spectively. In both cases the data indicated a slightly stronger in-
teraction than that of 17-AAG, an established HSP90 inhibitor
(45) (Fig. 3D).
Inhibition of CDPK1 has no effect on asexual parasite devel-
opment. To unequivocally determine the effect of inhibiting
CDPK1 on asexual blood stage parasite development, we adopted
a chemical genetics approach. Modification of the gatekeeper res-
idue of a kinase can alter its sensitivity to a group of large inhibi-
tors known as bumped kinase inhibitors (BKIs). Kinases with
large gatekeeper residues tend to be insensitive to these inhibitors,
whereas those with small gatekeeper residues are more sensitive
(46, 47). The CDPK1 T145G enzyme, which has the smallest
amino acid—glycine—at this position, has kinase activity in line
with that of the wild-type enzyme and is sensitive to inhibition by
the imidazopyridazine compounds (23). We tested two chemi-
cally related BKIs, NA-PP1 and NM-PP1, which are identical ex-
cept for the extended methylene linker of NM-PP1, which causes
the orientation of the napthyl group to change relative to the pyra-
zolopyrimidine core (Fig. 4A). Both of these compounds are re-
TABLE 2 Class 1 compounds inhibit PKG, and their potency against both the enzyme and the parasite is reduced by a larger gatekeeper residue
Class and
compounda
Aromatic
linker
Enzyme inhibition (IC50 [M])
b
Selectivity (PKG T618Q/
PKG IC50 ratio)
Parasite inhibition (EC50
[M])c
3D7 PKG
T618Q/3D7 EC50
ratioCDPK1 PKG PKG T618Q 3D7
3D7 PKG
T618Q
Class 1
28 Pyrimidine 0.012 0.003 31.69 10,563 0.059 0.640 10.8
36 (Cpd A) Pyrimidine 0.008 0.002 10.96 5,480 0.034 (0.006) 0.901 (0.483) 26.5
38 Pyrimidine 0.008 0.004 43.52 10,880 0.073 0.859 11.8
39 (Cpd B) Pyrimidine 0.009 0.002 25.54 12,770 0.034 0.982 28.9
41 (Cpd C) Pyrimidine 0.011 0.013 12.70 977 0.042 (0.018) 0.923 (0.226) 22.0
44 Pyrimidine 0.065 ND ND 0.236 0.477 2.0
Class 2
7 (Cpd D) Pyridine 0.013 0.484 15.51 32 0.427 (0.045) 0.477 (0.180) 1.1
20 (Cpd E) Fluoropyridine 0.008 0.012 15.33 1,278 0.210 0.386 1.8
22 Pyridine 0.074 1 37.53 38 0.215 0.303 1.4
42 Pyridine 0.081 ND ND 0.836 1.231 1.5
43 Pyridine 0.088 ND ND 0.080 0.093 1.2
Cpd 1 0.303 1.974 6.5
a Cpd, compound.
b Class 1 pyrimidine-linked compounds in particular display potent inhibition of PKG but not of the T618Q variant. ND, not determined.
c Parasite inhibition data are calculated from a single experiment, other than duplicate assays performed on compounds A, C, and D. For these compounds, the mean EC50 values
are shown, with the standard deviations from the means in parentheses.
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versible, cell-permeable inhibitors of small gatekeeper residue ki-
nases and have been used in both mammalian (48, 49) and
Saccharomyces cerevisiae cells (47, 50). CDPK1 T145G was 41
times more sensitive than the wild-type enzyme to inhibition by
NA-PP1, with IC50s of 0.15 and 6.01 M, respectively, and 13
times more sensitive to NM-PP1 than the wild-type enzyme, with
IC50s of 0.12 and 1.50 M, respectively (Fig. 4B). We used statis-
tical analysis within GraphPad Prism to compare the individual
curve fits for each data set with a curve fit to all the data sets, with
a null hypothesis that the IC50s are the same for both data sets. An
extra-sum-of-squares F test was used to compare the goodness of
fit of the two alternative models. A P value of 0.0001 indicated
that one curve did not fit to both data sets as well as individual
curves and that the IC50s are therefore significantly different for
both inhibitors with the two variant enzymes.
Having established this differential sensitivity of a gatekeeper
variant CDPK1, we generated by homologous recombination at
the endogenous gene locus a parasite line that expressed CDPK1
T145G. The transgenic parasite was engineered to also express a
triple HA tag at the extreme C terminus of the enzyme. A control
parasite line was made using an identical targeting approach in
which a triple HA tag was added to the protein, but no amino acid
substitution was introduced at the gatekeeper residue (Fig. 4C).
Using an anti-HA antibody on Western blots of schizont lysates
from the parasite lines, the modified proteins were the expected
size, and there was no evidence of unmodified protein in either
line (Fig. 4D, panel i). The T145G variant proteinwas expressed in
late-stage schizonts and targeted to the periphery of merozoites in
the same way as the wild-type enzyme (Fig. 4D, panel ii). The two
parasite lines were incubated with NA-PP1 and NM-PP1, and the
EC50s for each compound were calculated (Fig. 4E). The EC50s for
NA-PP1were 14.26Mfor 3D7CDPK1 T145T and 15.65Mfor
3D7 CDPK1 T145G. For NM-PP1 the EC50s were 11.55 M and
10.28Mfor 3D7CDPK1T145T and 3D7CDPK1T145Tparasite
lines, respectively. An extra-sum-of-squares F test to compare the
fit of one curve to both data sets with that of individual curves for
each data set, with a null hypothesis that the same curve could fit
both data sets, gave a P value of 0.70 for NA-PP1 treatment of the
two parasite lines and of 0.79 for NM-PP1, indicating that the
same curve could be used to fit the data for both parasite lines with
the inhibitors and that there is no significant difference between
the sensitivities of the parasite lines to either of the BKIs. These
data suggest that inhibition of CDPK1 has no effect on asexual
parasite viability.
DISCUSSION
The need for novel drugs against malaria has resulted in the emer-
gence of protein kinases as potential new targets (7).While little is
known about their detailed role in the biology of the parasite,
evidence from reverse genetics approaches regarding the essenti-
FIG 3 Affinity purification of cellular targets of compound D. (A) Biotin linked to the R1 group of compound D. This compound was bound to streptavidin-
agarose and used to affinity purify proteins from a trophozoite cell lysate. The only significant hit identified by LC-MS/MS was HSP90 (see Table S3 in the
supplemental material). (B) Predicted interactions between compound D and PfHSP90. (C)Modeling of the most likely binding orientation of compound D to
the ATP binding site of HSP90 was carried out using DockingServer. Residues predicted to form hydrogen bonds with compound D are labeled in green, while
those predicted to form hydrophobic interactions are labeled in blue. (D) Recombinant PfHSP90 binds to compound D. Purified recombinant PfHSP90 and
PfHSP90-NTD used in subsequent experiments are shown in the Coomassie-stained gels to the left of the figure. Changes in the tryptophan fluorescence (346
nm) of PfHSP90 weremonitored in the presence of increasing amounts of compoundD or 17-AAG.Kd values were calculated for both full-length (FL) PfHSP90
and PfHSP90-NTD. Values in brackets are the standard errors (SE) of the means of triplicate measurements.
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ality of a kinase has guided target selection (12). One such kinase is
PfCDPK1,which had been thought to be essential in asexual blood
stages due to an inability to disrupt the gene inP. falciparum andP.
berghei (15, 16).
We have characterized a series of imidazopyridazines that were
developed as CDPK1 inhibitors (20–23). We show here that the
parasiticidal activity of the compounds falls into two distinct
classes based on the timing of action during the asexual cycle of P.
falciparum. Furthermore, we established that the stage in the asex-
ual cycle at which the compounds act is governed by the nature of
the aromatic linker group. Class 1 compounds with a pyrimidine
ring at this position killed parasites at late schizogony by inhibi-
tion of PKG. Class 2 compounds with a nonpyrimidine moiety at
this position caused parasite death at the trophozoite stage, prob-
ably by inhibiting the activity of HSP90. It is remarkable that the
mode of action of the inhibitors is changed by relatively small
changes in the aromatic linker group.
We have demonstrated that the primary target of class 1 imi-
dazopyridazines is PKG, and the consequence of this inhibition is
a failure of merozoites to egress from schizonts. Although we had
shown previously that CDPK1 is potently inhibited by these com-
pounds (23), it appears that inhibition of CDPK1 has no effect on
parasite development: when an effect on PKG is discounted by
using a parasite expressing an inhibitor-insensitive PKG, the par-
FIG 4 Inhibition of PfCDPK1 has no effect on asexual parasite growth. (A) Chemical structures of the bumped kinase inhibitors (BKIs) NA-PP1 and NM-PP1.
(B) Recombinant CDPK1 with a glycine at the gatekeeper residue (amino acid 145) shows increased sensitivity to both BKIs. A ParM ADP biosensor assay to
measure ATPase activity of CDPK1 enzymes was carried out in the presence of serial dilutions of BKIs. The IC50 of CDPK1 T145G for NA-PP1 decreased 41-fold
compared to that of WT CDPK1, with IC50s of 0.15 M (95% confidence interval, 0.08 to 0.26 M) and 6.01 M (95% confidence interval, 3.4 to 10.5 M),
respectively. The IC50 of NM-PP1 was 0.12 M (95% confidence interval, 0.06 to 0.23 M) for CDPK1 T145G compared to 1.5 M (95% confidence interval,
0.77 to 2.90M) forWTCDPK1, a 13-fold decrease. Graphs showmean values fromfive independent experiments, with error bars indicating the standard errors
of the means. (C) Scheme for generating a P. falciparum 3D7 CDPK1 T145G-HA parasite line by single-crossover homologous recombination at the cdpk1
genomic locus. Crossover upstreamof the T145 codon is forced by recodonizing sequences downstreamof and including the T145 codon. Integration at the locus
results in a chimeric cdpk1 gene with a modified gatekeeper residue. An identical method was used in which the gatekeeper residue was left as a threonine to
generate the parasite line 3D7CDPK1T145T-HA.UTR, untranslated region. (D, panel i)Whole-cell lysates fromP. falciparum 3D7, 3D7CDPK1T145T-HA (T),
and 3D7 CDPK1 T145G-HA (G) were probed with antibodies against CDPK1 and against the HA epitope tag. Immunofluorescence using anti-HA and
anti-CDPK1 antibodies confirms that CDPK1 T145G-HA localizes correctly to the plasma membrane of parasites (panel ii). Scale bar, 1 m. (E) SYBR green
assays tomeasure the EC50s of NA-PP1 andNM-PP1 for P. falciparum 3D7CDPK1 T145T-HA and 3D7CDPK1 T145G-HA lines. The EC50 for NA-PP1 for 3D7
CDPK1T145T-HAwas 14.26M(95%confidence interval, 12.3 to 16.5M), and that for 3D7CDPK1T145G-HAwas 15.65M(95%confidence interval, 13.4
to 18.3M). The EC50s for NM-PP1 were 11.55M(95% confidence interval, 9.1 to 14.6M) and 10.28M(95% confidence interval, 8.1 to 13.0M) for 3D7
CDPK1 T145T-HA and 3D7 CDPK1 T145G-HA, respectively. The experiments were performed three times, with at least six replicate samples per experiment.
Graphs show mean values from three independent experiments, with error bars indicating the standard errors of the means.
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asite’s sensitivity to the compounds is very substantially reduced.
If inhibition of CDPK1 contributed to the observed effect on
merozoite egress, then we would have expected the PKG T618Q
parasite line to retain sensitivity to these compounds, which it
did not.
The identification of the protein chaperone HSP90 by affinity
purificationwith compoundDwas unexpected as the compounds
had been developed as kinase inhibitors. However, HSP90 has
essential ATPase activity, and it is likely that the class 2 imidazo-
pyridazine compounds bind to the ATP-binding site of both
HSP90 and CDPK1 even though these binding sites are quite dis-
similar. It is possible that the inhibitory phenotype seen in tropho-
zoites in the presence of class 2 compounds may be caused by the
inhibition of kinases or ATPases, in addition to HSP90, that were
not identified in the affinity purification using compound D.
However, it remains that HSP90 is a most promising candidate
based on the experiments we have presented here. The binding of
compoundD toHSP90 was confirmed experimentally. The use of
HSP90 inhibitors to block malaria parasite development is not a
new concept. Geldanamycin is a benzoquinone ansamycin known
to be an ATP-competitive inhibitor of human HSP90 (51). Both
geldanamycin and its derivative 17-AAG have been shown to
block parasite development at the trophozoite stage and to inhibit
the ATPase activity of P. falciparum HSP90 (32, 52). Another
HSP90 inhibitor is the purine analogue, PU-H71, which has an-
tiparasite activity in vitro and in vivo and displays a significant
synergistic effect with chloroquine (53). A series of 7-azaindole
compounds show exquisite binding selectivity for the parasite
HSP90 over the human isoforms and have been shown to inhibit
P. falciparum growth in culture (54). The class 2 imidazopyrida-
zines represent a new starting point to generate Plasmodium-spe-
cific HSP90 inhibitors.
Using a chemical genetics approach, we produced a P. falcipa-
rum line that expresses a CDPK1 gatekeeper variant that displays
increased sensitivity to bumped kinase inhibitors. There was no
difference in the sensitivities to either BKI of this parasite line and
one expressing an unchanged CDPK1. This supports the notion
that inhibiting CDPK1may not have an effect on parasite viability
and that the imidazopyridazine compounds kill parasites by inhi-
bition of other enzymes, despite their extremely potent inhibition
of CDPK1 activity in vitro (and presumably in vivo). Both of the
BKIs used in this study have been demonstrated to be cell perme-
able in several other systems (47–50), so it is reasonable to pre-
sume that P. falciparum is also accessible to inhibition with these
compounds. Similar chemical genetics approaches have been ad-
opted to study the orthologue of CDPK1 in Toxoplasma gondii,
TgCDPK3. Lourido and colleagues identified subtle differences in
gliding motility when parasites expressing TgCDPK3 with a gly-
cine gatekeeper residue were treated with BKIs, and the ability to
respond to ionophore-induced increases in intracellular calcium
was impaired (55). There are differences in parasite biology and
likely mechanisms of egress between T. gondii and P. falciparum,
and therefore direct extrapolation of results from either system to
the other may be unwise (56).
Our view that CDPK1 may not be essential in P. falciparum
asexual blood stages is supported by recent studies in P. berghei.
Sebastian and colleagues showed that when a promoter-swap ap-
proach to express P. berghei CDPK1 (PbCDPK1) at almost unde-
tectable levels in asexual blood stages was used, there was no effect
on parasite development during these stages (9). More recently,
while our investigations were ongoing, a study that knocked out
the Pbcdpk1 gene demonstrated conclusively that PbCDPK1 is
entirely dispensable in blood stages, with no effect on any stage of
asexual parasite development (17). There is no reason to think
that CDPK1 plays different roles in P. falciparum and P. berghei;
indeed Pfcdpk1 can substitute for Pbcdpk1 with no obvious effect
on P. berghei at any stage of development (R. Tewari, personal
communication).
Purfalcamine, a 2,6,9-trisubstituted purine, has been identified
as an inhibitor of PfCDPK1, and in its presence P. falciparum
parasites accumulate in late schizogony, with a block ofmerozoite
egress (15). While there is no doubt that purfalcamine potently
inhibits recombinant CDPK1, it is possible that it exerts its para-
siticidal effect by inhibiting enzymes other than CDPK1, such as
PKG, or perhaps other CDPKs, such as CDPK4 or CDPK5, which
is known to be involved inmerozoite egress (57). It will be impor-
tant to establish whether the parasiticidal effect of purfalcamine is
sensitive to the size of the PKG gatekeeper residue.
Target validation for drug discovery can be a complex pro-
cess, and extrapolating from genetic knockout studies to the
consequences of inhibition by small molecules can be problem-
atic (58). Where the phenotype of a genetic knockout is in
doubt, target-based drug discovery can lead to the erroneous
attribution of off-target activities of compounds to the protein
of interest. The evidence we have presented casts considerable
doubt on the suitability of CDPK1 as a drug target for blood
stage Plasmodium infections. While CDPK1 may represent a tar-
get for transmission-blocking treatment, owing to its proven role
in the sexual stages of the parasite (9), it seems that inhibition of
the enzyme during the asexual cycle causes no measurable reduc-
tion in fitness of the parasite, and as such CDPK1 may not be
worth pursuing as a drug target for the asexual stages of Plasmo-
dium.
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